Intuitive Surgical (NASDAQ: ISRG) saw its shares decline sharply in premarket trading on Friday, July 17, 2026, following the release of its second-quarter results and a cautious outlook for the remainder of the year. The stock was indicated at $357, down 11.3% from Thursday's close, putting the company on track to lose approximately $16.3 billion in market capitalization.
The sell-off was driven primarily by the company's guidance for the second half of 2026, which suggests a deceleration in da Vinci surgical procedure growth. According to Intuitive's projections, da Vinci procedure growth in the second half is expected to be around 13.8% at the midpoint of its guidance range, with the range spanning 11.9% to 15.7%. This compares to first-half growth of approximately 15.2%, indicating a notable slowdown.
For the full year, Intuitive estimates approximately 3.153 million da Vinci procedures. With 1.737 million procedures performed in the first half, the midpoint implies roughly 1.873 million procedures in the second half. This steady but slower growth trajectory weighed on investor sentiment, despite a solid quarterly performance.
In the second quarter, Intuitive reported revenue of $2.89 billion, up 19% year-over-year, and adjusted earnings of $2.80 per share. Both figures surpassed analyst expectations, which had called for $2.82 billion in revenue and $2.50 in adjusted earnings per share. The earnings beat included an eight-cent per share benefit from tariff refunds; even excluding that, adjusted profit exceeded forecasts. However, the market's focus remained on the forward-looking procedure outlook.
Global da Vinci procedures increased by 15% in the quarter, but U.S. procedure growth eased to 12%, down from 14% in the prior quarter. In contrast, international procedure growth accelerated to 20%. Intuitive installed 468 da Vinci systems during the quarter, including 246 of the new da Vinci 5 models, bringing the total installed base to 11,710 systems, up 12% year-over-year. Recurring revenue continued to be a key strength, accounting for 85% of total sales.
CEO Dave Rosa commented, "We are pleased with company performance this quarter," highlighting robust results across da Vinci, Ion, and digital tools. Despite the upbeat commentary, the market's reaction underscored concerns about the sustainability of growth in the face of a softer U.S. procedure environment.
Intuitive's valuation premium has narrowed following the results but remains elevated. At the premarket price of $357, the stock trades at an estimated trailing P/E of 43.4x, based on trailing earnings of $8.23 per share. This compares to Stryker (NYSE: SYK) at 38.3x and Medtronic (NYSE: MDT) at 23.3x, reflecting a 13% premium over Stryker and an 86% premium over Medtronic, though the companies have different business mixes.
Broader market conditions may amplify Friday's movement. Nasdaq 100 futures slipped 2.1% in premarket trading, adding to the negative sentiment. Additionally, HCA Healthcare (NYSE: HCA) issued an early warning, with preliminary second-quarter data showing a 2.3% decline in inpatient surgeries and a 3.4% drop in outpatient surgeries. While not directly comparable to Intuitive's global procedure totals, the data raises questions about hospital surgical volumes and payer mix, which will be a focus during HCA's earnings call on July 24.
Risks to Intuitive's outlook include potentially softer U.S. procedure trends, which could be short-lived, as well as headwinds from tariffs, uninsured procedure volumes, and hospital budget constraints. However, international growth remains solid, and recurring revenue continues to rise. The key question for investors is whether a valuation of 43 times earnings is justified by a mid-teens growth trajectory, especially as the second-half outlook points to moderation.
